| Year |
Citation |
Score |
| 2023 |
McNamara ME, Loyfer N, Kiliti AJ, Schmidt MO, Shabi-Porat S, Jain SS, Martinez Roth S, McDeed Iv AP, Shahrour N, Ballew E, Lin YT, Li HH, Deslattes Mays A, Rudra S, Riegel AT, ... ... Wellstein A, et al. Circulating cell-free methylated DNA reveals tissue-specific, cellular damage from radiation treatment. Jci Insight. PMID 37318863 DOI: 10.1172/jci.insight.156529 |
0.752 |
|
| 2021 |
Sharif GM, Campbell MJ, Nasir A, Sengupta S, Graham GT, Kushner MH, Kietzman WB, Schmidt MO, Pearson GW, Loudig O, Fineberg S, Wellstein A, Riegel AT. An AIB1 isoform alters enhancer access and enables progression of early stage triple-negative breast cancer. Cancer Research. PMID 34135000 DOI: 10.1158/0008-5472.CAN-20-3625 |
0.343 |
|
| 2020 |
Lin YN, Nasir A, Camacho S, Berry DL, Schmidt MO, Pearson GW, Riegel AT, Wellstein A. Monitoring Cancer Cell Invasion and T-Cell Cytotoxicity in 3D Culture. Journal of Visualized Experiments : Jove. PMID 32658183 DOI: 10.3791/61392 |
0.361 |
|
| 2020 |
Kushner MH, Graham G, Sharif G, Kietzman W, Glasgow E, Sangupta S, Wellstein A, Riegel AT. Abstract B41: Role of AIB1 in YAP-TEAD signaling in the progression of early-stage breast cancer Molecular Cancer Research. 18. DOI: 10.1158/1557-3125.Hippo19-B41 |
0.341 |
|
| 2019 |
Kushner MH, Ory V, Graham GT, Sharif GM, Kietzman WB, Thevissen S, Yuan M, Schmidt MO, Wellstein A, Riegel AT. Loss of ANCO1 repression at AIB1/YAP targets drives breast cancer progression. Embo Reports. e48741. PMID 31788936 DOI: 10.15252/Embr.201948741 |
0.383 |
|
| 2019 |
Kietzman WB, Graham GT, Ory V, Sharif G, Kushner MH, Gallanis GT, Kallakury B, Wellstein A, Riegel AT. Short and long-term effects of CDK4/6 inhibition on early stage breast cancer. Molecular Cancer Therapeutics. PMID 31451564 DOI: 10.1158/1535-7163.Mct-19-0231 |
0.409 |
|
| 2019 |
Saenz FR, Ory V, Schmidt MO, Kallakury BV, Mueller SC, Furth PA, Wellstein A, Riegel AT. Depletion of the Transcriptional Coactivator Amplified in Breast Cancer 1 (AIB1) Uncovers Functionally Distinct Subpopulations in Triple-Negative Breast Cancer. Neoplasia (New York, N.Y.). 21: 963-973. PMID 31437536 DOI: 10.1016/J.Neo.2019.07.001 |
0.415 |
|
| 2019 |
Deslattes Mays A, Schmidt M, Graham G, Tseng E, Baybayan P, Sebra R, Sanda M, Mazarati JB, Riegel A, Wellstein A. Single-Molecule Real-Time (SMRT) Full-Length RNA-Sequencing Reveals Novel and Distinct mRNA Isoforms in Human Bone Marrow Cell Subpopulations. Genes. 10. PMID 30934798 DOI: 10.3390/Genes10040253 |
0.755 |
|
| 2018 |
Vietsch EE, Graham GT, McCutcheon JN, Javaid A, Giaccone G, Marshall JL, Wellstein A. Reprint of: Circulating cell-free DNA mutation patterns in early and late stage colon and pancreatic cancer. Cancer Genetics. PMID 30447903 DOI: 10.1016/J.Cancergen.2018.11.001 |
0.323 |
|
| 2018 |
Tassi E, Garman KA, Schmidt MO, Ma X, Kabbara KW, Uren A, Tomita Y, Goetz R, Mohammadi M, Wilcox CS, Riegel AT, Carlstrom M, Wellstein A. Fibroblast Growth Factor Binding Protein 3 (FGFBP3) impacts carbohydrate and lipid metabolism. Scientific Reports. 8: 15973. PMID 30374109 DOI: 10.1038/S41598-018-34238-5 |
0.323 |
|
| 2018 |
Ory V, Kietzman WB, Boeckelman J, Kallakury BV, Wellstein A, Furth PA, Riegel AT. The PPARγ agonist efatutazone delays invasive progression and induces differentiation of ductal carcinoma in situ. Breast Cancer Research and Treatment. PMID 29350308 DOI: 10.1007/S10549-017-4649-Y |
0.306 |
|
| 2018 |
Lynn KD, Dominguez AT, Berens E, Toombs JE, Wellstein A, Brekken RA. Abstract B73: Pleiotrophin drives a pro-malignant macrophage phenotype in preclinical models of breast cancer Cancer Immunology Research. 6. DOI: 10.1158/2326-6074.Tumimm17-B73 |
0.383 |
|
| 2018 |
Saenz FR, Wellstein A, Riegel AT. Abstract A35: Characterizing the role of the nuclear coactivator AIB1 in triple-negative breast cancer Molecular Cancer Research. 16. DOI: 10.1158/1557-3125.Advbc17-A35 |
0.42 |
|
| 2017 |
Tassi E, Lai EY, Li L, Solis G, Chen Y, Kietzman WE, Ray PE, Riegel AT, Welch WJ, Wilcox CS, Wellstein A. Blood Pressure Control by a Secreted FGFBP1 (Fibroblast Growth Factor-Binding Protein). Hypertension (Dallas, Tex. : 1979). PMID 29158353 DOI: 10.1161/Hypertensionaha.117.10268 |
0.44 |
|
| 2017 |
Vietsch EE, Graham GT, McCutcheon JN, Javaid A, Giaccone G, Marshall JL, Wellstein A. Circulating cell-free DNA mutation patterns in early and late stage colon and pancreatic cancer. Cancer Genetics. 218: 39-50. PMID 29153095 DOI: 10.1016/J.Cancergen.2017.08.006 |
0.323 |
|
| 2017 |
Shivapurkar N, Vietsch EE, Carney E, Isaacs C, Wellstein A. Circulating microRNAs in patients with hormone receptor-positive, metastatic breast cancer treated with dovitinib. Clinical and Translational Medicine. 6: 37. PMID 28980224 DOI: 10.1186/S40169-017-0169-Y |
0.302 |
|
| 2017 |
Giamanco NM, Jee YH, Wellstein A, Shriver CD, Summers TA, Baron J. Midkine and pleiotrophin concentrations in needle biopsies of breast and lung masses. Cancer Biomarkers : Section a of Disease Markers. 20: 299-307. PMID 28946562 DOI: 10.3233/Cbm-170145 |
0.318 |
|
| 2017 |
Schmidt MO, Garman KA, Lee YG, Zuo C, Beck PJ, Tan M, Aguilar-Pimentel JA, Ollert M, Schmidt-Weber C, Fuchs H, Gailus-Durner V, Hrabe de Angelis M, Tassi E, Riegel AT, ... Wellstein A, et al. The Role of Fibroblast Growth Factor Binding Protein 1 in Skin Carcinogenesis and Inflammation. The Journal of Investigative Dermatology. PMID 28864076 DOI: 10.1016/J.Jid.2017.07.847 |
0.391 |
|
| 2017 |
Suprynowicz FA, Kamonjoh CM, Krawczyk E, Agarwal S, Wellstein A, Agboke FA, Choudhury S, Liu X, Schlegel R. Conditional cell reprogramming involves non-canonical β-catenin activation and mTOR-mediated inactivation of Akt. Plos One. 12: e0180897. PMID 28700668 DOI: 10.1371/Journal.Pone.0180897 |
0.349 |
|
| 2017 |
Berens EB, Gilardi M, Moretti M, Riegel AT, Wellstein A. Abstract 908: A role for MST4 in organelle organization and breast cancer cell vascular invasion Cancer Research. 77: 908-908. DOI: 10.1158/1538-7445.Am2017-908 |
0.33 |
|
| 2017 |
Kietzman WB, Ory V, Saenz F, Sharif G, Wellstein A, Riegel AT. Abstract 2357: CDK4/6 inhibition in early stage triple negative breast cancer Cancer Research. 77: 2357-2357. DOI: 10.1158/1538-7445.Am2017-2357 |
0.346 |
|
| 2016 |
Berens EB, Sharif GM, Wellstein A, Glasgow E. Testing the Vascular Invasive Ability of Cancer Cells in Zebrafish (Danio Rerio). Journal of Visualized Experiments : Jove. PMID 27842376 DOI: 10.3791/55007 |
0.369 |
|
| 2016 |
Berens EB, Sharif GM, Schmidt MO, Yan G, Shuptrine CW, Weiner LM, Glasgow E, Riegel AT, Wellstein A. Keratin-associated protein 5-5 controls cytoskeletal function and cancer cell vascular invasion. Oncogene. PMID 27375028 DOI: 10.1038/Onc.2016.234 |
0.415 |
|
| 2016 |
Rapisuwon S, Vietsch EE, Wellstein A. Circulating biomarkers to monitor cancer progression and treatment. Computational and Structural Biotechnology Journal. 14: 211-22. PMID 27358717 DOI: 10.1016/J.Csbj.2016.05.004 |
0.341 |
|
| 2016 |
Jee YH, Lebenthal Y, Chaemsaithong P, Yan G, Peran I, Wellstein A, Romero R, Baron J. Midkine and Pleiotrophin Concentrations in Amniotic Fluid in Healthy and Complicated Pregnancies. Plos One. 11: e0153325. PMID 27089523 DOI: 10.1371/Journal.Pone.0153325 |
0.356 |
|
| 2016 |
Tian X, Shivapurkar N, Wu Z, Hwang JJ, Pishvaian MJ, Weiner LM, Ley L, Zhou D, Zhi X, Wellstein A, Marshall JL, He AR. Circulating microRNA profile predicts disease progression in patients receiving second-line treatment of lapatinib and capecitabine for metastatic pancreatic cancer. Oncology Letters. 11: 1645-1650. PMID 26998056 DOI: 10.3892/Ol.2016.4101 |
0.31 |
|
| 2016 |
Jee YH, Sadowski SM, Celi FS, Xi L, Raffeld M, Sacks DB, Remaley AT, Wellstein A, Kebebew E, Baron J. Increased Pleiotrophin Concentrations in Papillary Thyroid Cancer. Plos One. 11: e0149383. PMID 26914549 DOI: 10.1371/Journal.Pone.0149383 |
0.323 |
|
| 2016 |
Berens EB, Sharif GM, Schmidt MO, Shuptrine CW, Weiner LM, Glasgow E, Riegel AT, Wellstein A. Abstract B44: Keratin-associated protein 5-5 controls cytoskeletal function and cancer cell vascular invasion Cancer Research. 76. DOI: 10.1158/1538-7445.Tummet15-B44 |
0.4 |
|
| 2016 |
Sharif GM, Schmidt MO, Shuptrine C, Louis WM, Riegel AT, Wellstein A. Abstract A15: SMC2 role in regulating tumor angiogenesis via FGF signaling Cancer Research. 76. DOI: 10.1158/1538-7445.Tummet15-A15 |
0.475 |
|
| 2015 |
Berens EB, Holy JM, Riegel AT, Wellstein A. A Cancer Cell Spheroid Assay to Assess Invasion in a 3D Setting. Journal of Visualized Experiments : Jove. PMID 26649463 DOI: 10.3791/53409 |
0.349 |
|
| 2015 |
Sharif GM, Wellstein A. Cell density regulates cancer metastasis via the Hippo pathway. Future Oncology (London, England). 11: 3253-60. PMID 26561730 DOI: 10.2217/Fon.15.268 |
0.405 |
|
| 2015 |
Vietsch EE, van Eijck CH, Wellstein A. Circulating DNA and Micro-RNA in Patients with Pancreatic Cancer. Pancreatic Disorders & Therapy. 5. PMID 26161297 DOI: 10.4172/2165-7092.1000156 |
0.348 |
|
| 2015 |
Sharif GM, Schmidt MO, Yi C, Hu Z, Haddad BR, Glasgow E, Riegel AT, Wellstein A. Cell growth density modulates cancer cell vascular invasion via Hippo pathway activity and CXCR2 signaling. Oncogene. PMID 25772246 DOI: 10.1038/Onc.2015.44 |
0.422 |
|
| 2015 |
Vietsch EE, Simmons JK, Peran I, Stenstra M, Mock BA, Wellstein A. Abstract A73: De-convoluting therapeutic resistance in a pancreatic cancer model: Pharmacogenomic evaluation of intratumoral clonal heterogeneity Cancer Research. 75. DOI: 10.1158/1538-7445.Panca2014-A73 |
0.352 |
|
| 2014 |
Ray PE, Al-Attar A, Liu XH, Das JR, Tassi E, Wellstein A. Expression of a Secreted Fibroblast Growth Factor Binding Protein-1 (FGFBP1) in Angioproliferative Kaposi Sarcoma. Journal of Aids & Clinical Research. 5. PMID 25429350 DOI: 10.4172/2155-6113.1000309 |
0.663 |
|
| 2014 |
Saenz FR, Ory V, AlOtaiby M, Rosenfield S, Furlong M, Cavalli LR, Johnson MD, Liu X, Schlegel R, Wellstein A, Riegel AT. Conditionally reprogrammed normal and transformed mouse mammary epithelial cells display a progenitor-cell-like phenotype. Plos One. 9: e97666. PMID 24831228 DOI: 10.1371/Journal.Pone.0097666 |
0.41 |
|
| 2014 |
Zhang W, Nandakumar N, Shi Y, Manzano M, Smith A, Graham G, Gupta S, Vietsch EE, Laughlin SZ, Wadhwa M, Chetram M, Joshi M, Wang F, Kallakury B, Toretsky J, ... Wellstein A, et al. Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma. Science Signaling. 7: ra42. PMID 24803537 DOI: 10.1126/Scisignal.2005049 |
0.413 |
|
| 2014 |
Kolukula VK, Sahu G, Wellstein A, Rodriguez OC, Preet A, Iacobazzi V, D'Orazi G, Albanese C, Palmieri F, Avantaggiati ML. SLC25A1, or CIC, is a novel transcriptional target of mutant p53 and a negative tumor prognostic marker. Oncotarget. 5: 1212-25. PMID 24681808 DOI: 10.18632/Oncotarget.1831 |
0.378 |
|
| 2014 |
Garee JP, Chien CD, Li JV, Wellstein A, Riegel AT. Regulation of HER2 oncogene transcription by a multifunctional coactivator/corepressor complex. Molecular Endocrinology (Baltimore, Md.). 28: 846-59. PMID 24678732 DOI: 10.1210/Me.2013-1379 |
0.356 |
|
| 2014 |
Shivapurkar N, Weiner LM, Marshall JL, Madhavan S, Deslattes Mays A, Juhl H, Wellstein A. Recurrence of early stage colon cancer predicted by expression pattern of circulating microRNAs. Plos One. 9: e84686. PMID 24400111 DOI: 10.1371/Journal.Pone.0084686 |
0.746 |
|
| 2014 |
Ory V, Tassi E, Cavalli LR, Sharif GM, Saenz F, Baker T, Schmidt MO, Mueller SC, Furth PA, Wellstein A, Riegel AT. The nuclear coactivator amplified in breast cancer 1 maintains tumor-initiating cells during development of ductal carcinoma in situ. Oncogene. 33: 3033-42. PMID 23851504 DOI: 10.1038/Onc.2013.263 |
0.42 |
|
| 2014 |
Laiakis EC, LaConti JJ, Cheema A, Wellstein A, Fornace AJ. Addition of metabolomics to the omics spectrum for cancer biomarker development– demonstration with the KrasG12D mouse model for pancreatic carcinoma Bmc Genomics. 15. DOI: 10.1186/1471-2164-15-S2-O4 |
0.321 |
|
| 2013 |
Li JV, Chien CD, Garee JP, Xu J, Wellstein A, Riegel AT. Transcriptional repression of AIB1 by FoxG1 leads to apoptosis in breast cancer cells. Molecular Endocrinology (Baltimore, Md.). 27: 1113-27. PMID 23660594 DOI: 10.1210/Me.2012-1353 |
0.413 |
|
| 2013 |
Rosenfield SM, Bowden ET, Cohen-Missner S, Gibby KA, Ory V, Henke RT, Riegel AT, Wellstein A. Correction: Pleiotrophin (PTN) expression and function in the mouse mammary gland and mammary epithelial cells (PLoS ONE) Plos One. 8. DOI: 10.1371/annotation/55d244a2-0960-4f5f-95e9-2eea136654b1 |
0.781 |
|
| 2013 |
Sharif GM, Schmidt MO, Hu Z, Glasgow E, Riegel AT, Wellstein A. Abstract B63: Cancer cell invasion determined by cell density-dependent, cytokine-mediated crosstalk Cancer Research. 73. DOI: 10.1158/1538-7445.Tim2013-B63 |
0.414 |
|
| 2013 |
Wu Z, Shivapurkar N, Marshall JL, Hwang J, Pishvaian MJ, Zhuang T, Wellstein A, Weiner LM, Ley L, He AR. Abstract 4667: Circulating microRNA profile predicts disease progression in patients receiving second-line treatment of lapatinib and capecitabine for metastatic pancreatic cancer. Cancer Research. 73: 4667-4667. DOI: 10.1158/1538-7445.Am2013-4667 |
0.309 |
|
| 2013 |
Sharif GM, Schmidt MO, Shuptrine C, Weiner LM, Hu Z, Riegel AT, Wellstein A. Abstract 2689: Drivers of cancer cell invasion and metastasis. Cancer Research. 73: 2689-2689. DOI: 10.1158/1538-7445.Am2013-2689 |
0.384 |
|
| 2013 |
Ory V, Tassi E, Cavalli L, Saenz F, Baker T, Mueller S, Furth P, Wellstein A, Riegel A. Abstract 1404: The nuclear coactivator amplified in breast cancer 1 promotes the initiation and the development of ductal carcinomain situ. Cancer Research. 73: 1404-1404. DOI: 10.1158/1538-7445.Am2013-1404 |
0.407 |
|
| 2013 |
Ory V, Tassi E, Cavalli L, Sharif G, Saenz F, Baker T, Schmidt M, Mueller S, Furth P, Wellstein A, Riegel A. Abstract P5-07-03: The nuclear coactivator amplified in breast cancer 1 maintains tumor initiating cells during development of ductal carcinoma in situ Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-P5-07-03 |
0.364 |
|
| 2012 |
Wellstein A. ALK receptor activation, ligands and therapeutic targeting in glioblastoma and in other cancers. Frontiers in Oncology. 2: 192. PMID 23267434 DOI: 10.3389/Fonc.2012.00192 |
0.417 |
|
| 2012 |
Rosenfield SM, Bowden ET, Cohen-Missner S, Gibby KA, Ory V, Henke RT, Riegel AT, Wellstein A. Pleiotrophin (PTN) expression and function and in the mouse mammary gland and mammary epithelial cells. Plos One. 7: e47876. PMID 23077670 DOI: 10.1371/Journal.Pone.0047876 |
0.798 |
|
| 2012 |
Al-Otaiby M, Tassi E, Schmidt MO, Chien CD, Baker T, Salas AG, Xu J, Furlong M, Schlegel R, Riegel AT, Wellstein A. Role of the nuclear receptor coactivator AIB1/SRC-3 in angiogenesis and wound healing. The American Journal of Pathology. 180: 1474-84. PMID 22342158 DOI: 10.1016/J.Ajpath.2011.12.032 |
0.437 |
|
| 2012 |
Wu Z, Marshall J, Hwang JJ, Pishvaian MJ, Wellstein A, Weiner LM, He AR. A phase II study of lapatinib and capecitabine in second-line treatment of metastatic pancreatic cancer. Journal of Clinical Oncology. 30. DOI: 10.1200/Jco.2012.30.15_Suppl.E14569 |
0.375 |
|
| 2011 |
He AR, Hwang JJ, Marshall J, Pishvaian M, Slack R, Weiner LM, Wellstein A. A phase II study of lapatinib and capecitabine in second line treatment of locally advanced/metastatic pancreatic cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: e14542. PMID 28020703 DOI: 10.1200/Jco.2011.29.15_Suppl.E14542 |
0.388 |
|
| 2011 |
Tassi E, McDonnell K, Gibby KA, Tilan JU, Kim SE, Kodack DP, Schmidt MO, Sharif GM, Wilcox CS, Welch WJ, Gallicano GI, Johnson MD, Riegel AT, Wellstein A. Impact of fibroblast growth factor-binding protein-1 expression on angiogenesis and wound healing. The American Journal of Pathology. 179: 2220-32. PMID 21945411 DOI: 10.1016/J.Ajpath.2011.07.043 |
0.802 |
|
| 2011 |
LaConti JJ, Shivapurkar N, Preet A, Deslattes Mays A, Peran I, Kim SE, Marshall JL, Riegel AT, Wellstein A. Tissue and serum microRNAs in the Kras(G12D) transgenic animal model and in patients with pancreatic cancer. Plos One. 6: e20687. PMID 21738581 DOI: 10.1371/Journal.Pone.0020687 |
0.752 |
|
| 2011 |
Hu ZZ, Kagan BL, Ariazi EA, Rosenthal DS, Zhang L, Li JV, Huang H, Wu C, Jordan VC, Riegel AT, Wellstein A. Proteomic analysis of pathways involved in estrogen-induced growth and apoptosis of breast cancer cells. Plos One. 6: e20410. PMID 21738574 DOI: 10.1371/Journal.Pone.0020410 |
0.355 |
|
| 2011 |
Chien CD, Kirilyuk A, Li JV, Zhang W, Lahusen T, Schmidt MO, Oh AS, Wellstein A, Riegel AT. Role of the nuclear receptor coactivator AIB1-Delta4 splice variant in the control of gene transcription. The Journal of Biological Chemistry. 286: 26813-27. PMID 21636853 DOI: 10.1074/Jbc.M110.216200 |
0.386 |
|
| 2011 |
Al-Otaiby MA, Zhangzhi H, Riegel A, Wellstein A. Abstract 3115: Role of nuclear coactivator AIB1 in endothelial cell function and angiogenesis Cancer Research. 71: 3115-3115. DOI: 10.1158/1538-7445.Am2011-3115 |
0.462 |
|
| 2010 |
LaConti JJ, Shivapurkar N, Preet A, Kim SE, Riegel AT, Wellstein A. Abstract 721: An anaplastic lymphoma kinase antibody targets pancreatic allografts, prevents the progression of pancreatic cancer, and induces changes in microRNA expression Cancer Research. 70: 721-721. DOI: 10.1158/1538-7445.Am10-721 |
0.364 |
|
| 2010 |
Kodack DP, LaConti J, Noda M, Wellstein A. Abstract 4018: Crosstalk between the pleiotrophin-anaplastic lymphoma kinase axis and the protein tyrosine phosphatase ζ signaling pathways Cancer Research. 70: 4018-4018. DOI: 10.1158/1538-7445.Am10-4018 |
0.431 |
|
| 2009 |
Stylianou DC, Auf der Maur A, Kodack DP, Henke RT, Hohn S, Toretsky JA, Riegel AT, Wellstein A. Effect of single-chain antibody targeting of the ligand-binding domain in the anaplastic lymphoma kinase receptor. Oncogene. 28: 3296-306. PMID 19633684 DOI: 10.1038/Onc.2009.184 |
0.801 |
|
| 2009 |
Gibby KA, McDonnell K, Schmidt MO, Wellstein A. A distinct role for secreted fibroblast growth factor-binding proteins in development. Proceedings of the National Academy of Sciences of the United States of America. 106: 8585-90. PMID 19433791 DOI: 10.1073/Pnas.0810952106 |
0.793 |
|
| 2009 |
Lahusen T, Henke RT, Kagan BL, Wellstein A, Riegel AT. The role and regulation of the nuclear receptor co-activator AIB1 in breast cancer. Breast Cancer Research and Treatment. 116: 225-37. PMID 19418218 DOI: 10.1007/S10549-009-0405-2 |
0.374 |
|
| 2008 |
Oh AS, Lahusen JT, Chien CD, Fereshteh MP, Zhang X, Dakshanamurthy S, Xu J, Kagan BL, Wellstein A, Riegel AT. Tyrosine phosphorylation of the nuclear receptor coactivator AIB1/SRC-3 is enhanced by Abl kinase and is required for its activity in cancer cells. Molecular and Cellular Biology. 28: 6580-93. PMID 18765637 DOI: 10.1128/Mcb.00118-08 |
0.409 |
|
| 2008 |
Bachis A, Mallei A, Cruz MI, Wellstein A, Mocchetti I. Chronic antidepressant treatments increase basic fibroblast growth factor and fibroblast growth factor-binding protein in neurons. Neuropharmacology. 55: 1114-20. PMID 18682257 DOI: 10.1016/J.Neuropharm.2008.07.014 |
0.31 |
|
| 2008 |
Zhang W, Chen Y, Swift MR, Tassi E, Stylianou DC, Gibby KA, Riegel AT, Wellstein A. Effect of FGF-binding protein 3 on vascular permeability. The Journal of Biological Chemistry. 283: 28329-37. PMID 18669637 DOI: 10.1074/Jbc.M802144200 |
0.773 |
|
| 2008 |
Fereshteh MP, Tilli MT, Kim SE, Xu J, O'Malley BW, Wellstein A, Furth PA, Riegel AT. The nuclear receptor coactivator amplified in breast cancer-1 is required for Neu (ErbB2/HER2) activation, signaling, and mammary tumorigenesis in mice. Cancer Research. 68: 3697-706. PMID 18483252 DOI: 10.1158/0008-5472.Can-07-6702 |
0.41 |
|
| 2007 |
Lahusen T, Fereshteh M, Oh A, Wellstein A, Riegel AT. Epidermal growth factor receptor tyrosine phosphorylation and signaling controlled by a nuclear receptor coactivator, amplified in breast cancer 1. Cancer Research. 67: 7256-65. PMID 17671194 DOI: 10.1158/0008-5472.Can-07-1013 |
0.402 |
|
| 2007 |
Tassi E, Walter S, Aigner A, Cabal-Manzano RH, Ray R, Reier PJ, Wellstein A. Effects on neurite outgrowth and cell survival of a secreted fibroblast growth factor binding protein upregulated during spinal cord injury. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology. 293: R775-83. PMID 17553847 DOI: 10.1152/Ajpregu.00737.2006 |
0.361 |
|
| 2007 |
Kuo AH, Stoica GE, Riegel AT, Wellstein A. Recruitment of insulin receptor substrate-1 and activation of NF-kappaB essential for midkine growth signaling through anaplastic lymphoma kinase. Oncogene. 26: 859-69. PMID 16878150 DOI: 10.1038/Sj.Onc.1209840 |
0.72 |
|
| 2006 |
Tassi E, Wellstein A. Tumor angiogenesis: initiation and targeting - therapeutic targeting of an FGF-binding protein, an angiogenic switch molecule, and indicator of early stages of gastrointestinal adenocarcinomas -. Cancer Research and Treatment : Official Journal of Korean Cancer Association. 38: 189-97. PMID 19771241 DOI: 10.4143/Crt.2006.38.4.189 |
0.467 |
|
| 2006 |
Tassi E, Wellstein A. The angiogenic switch molecule, secreted FGF-binding protein, an indicator of early stages of pancreatic and colorectal adenocarcinoma. Seminars in Oncology. 33: S50-6. PMID 17178288 DOI: 10.1053/J.Seminoncol.2006.10.014 |
0.437 |
|
| 2006 |
Mani A, Oh AS, Bowden ET, Lahusen T, Lorick KL, Weissman AM, Schlegel R, Wellstein A, Riegel AT. E6AP mediates regulated proteasomal degradation of the nuclear receptor coactivator amplified in breast cancer 1 in immortalized cells. Cancer Research. 66: 8680-6. PMID 16951183 DOI: 10.1158/0008-5472.Can-06-0557 |
0.416 |
|
| 2006 |
Henke RT, Eun Kim S, Maitra A, Paik S, Wellstein A. Expression analysis of mRNA in formalin-fixed, paraffin-embedded archival tissues by mRNA in situ hybridization. Methods (San Diego, Calif.). 38: 253-62. PMID 16513366 DOI: 10.1016/J.Ymeth.2005.11.013 |
0.301 |
|
| 2006 |
Tassi E, Henke RT, Bowden ET, Swift MR, Kodack DP, Kuo AH, Maitra A, Wellstein A. Expression of a fibroblast growth factor-binding protein during the development of adenocarcinoma of the pancreas and colon. Cancer Research. 66: 1191-8. PMID 16424058 DOI: 10.1158/0008-5472.Can-05-2926 |
0.755 |
|
| 2006 |
Ray PE, Tassi E, Liu XH, Wellstein A. Role of fibroblast growth factor-binding protein in the pathogenesis of HIV-associated hemolytic uremic syndrome. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology. 290: R105-13. PMID 16352855 DOI: 10.1152/Ajpregu.00492.2005 |
0.318 |
|
| 2006 |
Xie B, Tassi E, Swift MR, McDonnell K, Bowden ET, Wang S, Ueda Y, Tomita Y, Riegel AT, Wellstein A. Identification of the fibroblast growth factor (FGF)-interacting domain in a secreted FGF-binding protein by phage display. The Journal of Biological Chemistry. 281: 1137-44. PMID 16257968 DOI: 10.1074/Jbc.M510754200 |
0.393 |
|
| 2005 |
McDonnell K, Bowden ET, Cabal-Manzano R, Hoxter B, Riegel AT, Wellstein A. Vascular leakage in chick embryos after expression of a secreted binding protein for fibroblast growth factors. Laboratory Investigation; a Journal of Technical Methods and Pathology. 85: 747-55. PMID 15806140 DOI: 10.1038/Labinvest.3700269 |
0.472 |
|
| 2005 |
Malerczyk C, Schulte AM, Czubayko F, Bellon L, Macejak D, Riegel AT, Wellstein A. Ribozyme targeting of the growth factor pleiotrophin in established tumors: A gene therapy approach Gene Therapy. 12: 339-346. PMID 15496960 DOI: 10.1038/Sj.Gt.3302398 |
0.416 |
|
| 2004 |
Oh A, List HJ, Reiter R, Mani A, Zhang Y, Gehan E, Wellstein A, Riegel AT. The nuclear receptor coactivator AIB1 mediates insulin-like growth factor I-induced phenotypic changes in human breast cancer cells. Cancer Research. 64: 8299-308. PMID 15548698 DOI: 10.1158/0008-5472.Can-04-0354 |
0.432 |
|
| 2004 |
Kurtz A, Aigner A, Cabal-Manzano RH, Butler RE, Hood DR, Sessions RB, Czubayko F, Wellstein A. Differential regulation of a fibroblast growth factor-binding protein during skin carcinogenesis and wound healing. Neoplasia (New York, N.Y.). 6: 595-602. PMID 15548369 DOI: 10.1593/Neo.04214 |
0.374 |
|
| 2004 |
Henke RT, Haddad BR, Kim SE, Rone JD, Mani A, Jessup JM, Wellstein A, Maitra A, Riegel AT. Overexpression of the nuclear receptor coactivator AIB1 (SRC-3) during progression of pancreatic adenocarcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 6134-42. PMID 15448000 DOI: 10.1158/1078-0432.Ccr-04-0561 |
0.409 |
|
| 2004 |
Burbelo P, Wellstein A, Pestell RG. Altered Rho GTPase signaling pathways in breast cancer cells. Breast Cancer Research and Treatment. 84: 43-8. PMID 14999153 DOI: 10.1023/B:Brea.0000018422.02237.F9 |
0.371 |
|
| 2004 |
Reiter R, Oh AS, Wellstein A, Riegel AT. Impact of the nuclear receptor coactivator AIB1 isoform AIB1-Delta3 on estrogenic ligands with different intrinsic activity. Oncogene. 23: 403-9. PMID 14691461 DOI: 10.1038/Sj.Onc.1207202 |
0.327 |
|
| 2004 |
Gvozdjan DM, Bowden ET, Wellstein A. A novel chicken embryo model for the investigation of drugs with antimetastatic properties Clinical Pharmacology & Therapeutics. 75: 60. DOI: 10.1016/J.Clpt.2003.11.229 |
0.324 |
|
| 2003 |
Stoica GE, Franke TF, Moroni M, Mueller S, Morgan E, Iann MC, Winder AD, Reiter R, Wellstein A, Martin MB, Stoica A. Effect of estradiol on estrogen receptor-alpha gene expression and activity can be modulated by the ErbB2/PI 3-K/Akt pathway. Oncogene. 22: 7998-8011. PMID 12970748 DOI: 10.1038/Sj.Onc.1206769 |
0.378 |
|
| 2003 |
Stoica GE, Franke TF, Wellstein A, Morgan E, Czubayko F, List HJ, Reiter R, Martin MB, Stoica A. Heregulin-beta1 regulates the estrogen receptor-alpha gene expression and activity via the ErbB2/PI 3-K/Akt pathway. Oncogene. 22: 2073-87. PMID 12687010 DOI: 10.1038/Sj.Onc.1206311 |
0.309 |
|
| 2003 |
Kagan BL, Henke RT, Cabal-Manzano R, Stoica GE, Nguyen Q, Wellstein A, Riegel AT. Complex regulation of the fibroblast growth factor-binding protein in MDA- MB-468 breast cancer cells by CCAAT/enhancer-binding protein beta. Cancer Research. 63: 1696-705. PMID 12670924 |
0.368 |
|
| 2003 |
Stoica GE, Franke TF, Wellstein A, Czubayko F, List HJ, Reiter R, Morgan E, Martin MB, Stoica A. Estradiol rapidly activates Akt via the ErbB2 signaling pathway. Molecular Endocrinology (Baltimore, Md.). 17: 818-30. PMID 12554767 DOI: 10.1210/Me.2002-0330 |
0.38 |
|
| 2002 |
Lauritsen KJ, List HJ, Reiter R, Wellstein A, Riegel AT. A role for TGF-beta in estrogen and retinoid mediated regulation of the nuclear receptor coactivator AIB1 in MCF-7 breast cancer cells. Oncogene. 21: 7147-55. PMID 12370804 DOI: 10.1038/Sj.Onc.1205943 |
0.395 |
|
| 2002 |
Stoica GE, Kuo A, Powers C, Bowden ET, Sale EB, Riegel AT, Wellstein A. Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types. The Journal of Biological Chemistry. 277: 35990-8. PMID 12122009 DOI: 10.1074/Jbc.M205749200 |
0.81 |
|
| 2002 |
Bowden ET, Stoica GE, Wellstein A. Anti-apoptotic signaling of pleiotrophin through its receptor, anaplastic lymphoma kinase. The Journal of Biological Chemistry. 277: 35862-8. PMID 12107166 DOI: 10.1074/Jbc.M203963200 |
0.389 |
|
| 2002 |
Jäger R, List B, Knabbe C, Souttou B, Raulais D, Zeiler T, Wellstein A, Aigner A, Neubauer A, Zugmaier G. Serum levels of the angiogenic factor pleiotrophin in relation to disease stage in lung cancer patients British Journal of Cancer. 86: 858-863. PMID 11953815 DOI: 10.1038/Sj.Bjc.6600202 |
0.357 |
|
| 2002 |
Aigner A, Ray PE, Czubayko F, Wellstein A. Immunolocalization of an FGF-binding protein reveals a widespread expression pattern during different stages of mouse embryo development. Histochemistry and Cell Biology. 117: 1-11. PMID 11819092 DOI: 10.1007/S00418-001-0360-4 |
0.456 |
|
| 2002 |
Powers C, Aigner A, Stoica GE, McDonnell K, Wellstein A. Pleiotrophin signaling through anaplastic lymphoma kinase is rate-limiting for glioblastoma growth. The Journal of Biological Chemistry. 277: 14153-8. PMID 11809760 DOI: 10.1074/Jbc.M112354200 |
0.679 |
|
| 2001 |
List HJ, Reiter R, Singh B, Wellstein A, Riegel AT. Expression of the nuclear coactivator AIB1 in normal and malignant breast tissue Breast Cancer Research and Treatment. 68: 21-28. PMID 11678305 DOI: 10.1023/A:1017910924390 |
0.359 |
|
| 2001 |
Tassi E, Al-Attar A, Aigner A, Swift MR, McDonnell K, Karavanov A, Wellstein A. Enhancement of fibroblast growth factor (FGF) activity by an FGF-binding protein. The Journal of Biological Chemistry. 276: 40247-53. PMID 11509569 DOI: 10.1074/Jbc.M104933200 |
0.69 |
|
| 2001 |
Reiter R, Wellstein A, Riegel AT. An Isoform of the Coactivator AIB1 that Increases Hormone and Growth Factor Sensitivity Is Overexpressed in Breast Cancer Journal of Biological Chemistry. 276: 39736-39741. PMID 11502741 DOI: 10.1074/Jbc.M104744200 |
0.407 |
|
| 2001 |
List HJ, Lauritsen KJ, Reiter R, Powers C, Wellstein A, Riegel AT. Ribozyme Targeting Demonstrates That the Nuclear Receptor Coactivator AIB1 Is a Rate-limiting Factor for Estrogen-dependent Growth of Human MCF-7 Breast Cancer Cells Journal of Biological Chemistry. 276: 23763-23768. PMID 11328819 DOI: 10.1074/Jbc.M102397200 |
0.67 |
|
| 2001 |
Liu XH, Aigner A, Wellstein A, Ray PE. Up-regulation of a fibroblast growth factor binding protein in children with renal diseases Kidney International. 59: 1717-1728. PMID 11318942 DOI: 10.1046/J.1523-1755.2001.0590051717.X |
0.333 |
|
| 2001 |
Harris VK, Kagan BL, Ray R, Coticchia CM, Liaudet-Coopman ED, Wellstein A, Tate Riegel A. Serum induction of the fibroblast growth factor-binding protein (FGF-BP) is mediated through ERK and p38 MAP kinase activation and C/EBP-regulated transcription. Oncogene. 20: 1730-8. PMID 11313920 DOI: 10.1038/Sj.Onc.1204249 |
0.446 |
|
| 2001 |
Aigner A, Butscheid M, Kunkel P, Krause E, Lamszus K, Wellstein A, Czubayko F. An FGF-binding protein (FGF-BP) exerts its biological function by parallel paracrine stimulation of tumor cell and endothelial cell proliferation through FGF-2 release International Journal of Cancer. 92: 510-517. PMID 11304685 DOI: 10.1002/1097-0215(20010515)92:4<510::Aid-Ijc1227>3.0.Co;2-H |
0.475 |
|
| 2001 |
Stoica GE, Kuo A, Aigner A, Sunitha I, Souttou B, Malerczyk C, Caughey DJ, Wen D, Karavanov A, Riegel AT, Wellstein A. Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin. The Journal of Biological Chemistry. 276: 16772-9. PMID 11278720 DOI: 10.1074/Jbc.M010660200 |
0.768 |
|
| 2001 |
Wellstein A. The bacterial polysaccharide tecogalan blocks growth of breast cancer cells in vivo Oncology Reports. 8: 161-164. PMID 11115590 DOI: 10.3892/Or.8.1.161 |
0.442 |
|
| 2000 |
Boyle BJ, Harris VK, Liaudet-Coopman EDE, Riegel AT, Wellstein A. Differential regulation of a fibroblast growth factor-binding protein by receptor-selective analogs of retinoic acid Biochemical Pharmacology. 60: 1677-1684. PMID 11077050 DOI: 10.1016/S0006-2952(00)00507-4 |
0.427 |
|
| 2000 |
Powers CJ, McLeskey SW, Wellstein A. Fibroblast growth factors, their receptors and signaling. Endocrine-Related Cancer. 7: 165-97. PMID 11021964 DOI: 10.1677/Erc.0.0070165 |
0.689 |
|
| 2000 |
Weber D, Klomp HJ, Czubayko F, Wellstein A, Juhl H. Pleiotrophin can be rate-limiting for pancreatic cancer cell growth Cancer Research. 60: 5284-5288. PMID 11016659 |
0.335 |
|
| 2000 |
Schulte AM, Malerczyk C, Cabal-Manzano R, Gajarsa JJ, List HJ, Riegel AT, Wellstein A. Influence of the human endogenous retrovirus-like element HERV-E.PTN on the expression of growth factor pleiotrophin: A critical role of a retroviral Sp1-binding site Oncogene. 19: 3988-3998. PMID 10962555 DOI: 10.1038/Sj.Onc.1203742 |
0.401 |
|
| 2000 |
Harris VK, Coticchia CM, List HJ, Wellstein A, Riegel AT. Mitogen-induced expression of the fibroblast growth factor-binding protein is transcriptionally repressed through a non-canonical E-box element Journal of Biological Chemistry. 275: 28539-28548. PMID 10871606 DOI: 10.1074/Jbc.M001677200 |
0.407 |
|
| 2000 |
Aigner A, Malerczyk C, Houghtling R, Wellstein A. Tissue distribution and retinoid-mediated downregulation of an FGF-binding protein (FGF-BP) in the rat Growth Factors. 18: 51-62. PMID 10831072 DOI: 10.3109/08977190009003233 |
0.42 |
|
| 2000 |
Harris VK, Coticchia CM, Kagan BL, Ahmad S, Wellstein A, Riegel AT. Induction of the angiogenic modulator fibroblast growth factor-binding protein by epidermal growth factor is mediated through both MEK/ERK and p38 signal transduction pathways. The Journal of Biological Chemistry. 275: 10802-11. PMID 10753873 DOI: 10.1074/Jbc.275.15.10802 |
0.465 |
|
| 1999 |
Mashour GA, Wang HL, Cabal-Manzano R, Wellstein A, Martuza RL, Kurtz A. Aberrant cutaneous expression of the angiogenic factor midkine is associated with neurofibromatosis type-1. The Journal of Investigative Dermatology. 113: 398-402. PMID 10469340 DOI: 10.1046/J.1523-1747.1999.00699.X |
0.397 |
|
| 1999 |
List HJ, Lozano C, Lu J, Danielsen M, Wellstein A, Riegel AT. Comparison of chromatin remodeling and transcriptional activation of the mouse mammary tumor virus promoter by the androgen and glucocorticoid receptor Experimental Cell Research. 250: 414-422. PMID 10413595 DOI: 10.1006/Excr.1999.4517 |
0.347 |
|
| 1998 |
Souttou B, Juhl H, Hackenbruck J, Röckseisen M, Klomp HJ, Raulais D, Vigny M, Wellstein A. Relationship between serum concentrations of the growth factor pleiotrophin and pleiotrophin-positive tumors Journal of the National Cancer Institute. 90: 1468-1473. PMID 9776412 DOI: 10.1093/Jnci/90.19.1468 |
0.385 |
|
| 1998 |
Harris VK, Liaudet-Coopman EDE, Boyle BJ, Wellstein A, Riegel AT. Phorbol ester-induced transcription of a fibroblast growth factor- binding protein is modulated by a complex interplay of positive and negative regulatory promoter elements Journal of Biological Chemistry. 273: 19130-19139. PMID 9668098 DOI: 10.1074/Jbc.273.30.19130 |
0.439 |
|
| 1998 |
Kurtz A, Spitzer E, Zschiesche W, Wellstein A, Grosse R. Local control of mammary gland differentiation: Mammary-derived growth inhibitor and pleiotrophin Biochemical Society Symposium. 63: 51-69. |
0.334 |
|
| 1997 |
Liaudet-Coopman EDE, Berchem GJ, Wellstein A. In vivo inhibition of angiogenesis and induction of apoptosis by retinoic acid in squamous cell carcinoma Clinical Cancer Research. 3: 179-184. PMID 9815670 |
0.347 |
|
| 1997 |
Juhl H, Downing SG, Wellstein A, Czubayko F. HER-2/neu is rate-limiting for ovarian cancer growth. Conditional depletion of HER-2/neu by ribozyme targeting Journal of Biological Chemistry. 272: 29482-29486. PMID 9368008 DOI: 10.1074/Jbc.272.47.29482 |
0.469 |
|
| 1997 |
Czubayko F, Downing SG, Hsieh SS, Goldstein DJ, Lu PY, Trapnell BC, Wellstein A. Adenovirus-mediated transduction of ribozymes abrogates HER-2/neu and pleiotrophin expression and inhibits tumor cell proliferation. Gene Therapy. 4: 943-9. PMID 9349431 DOI: 10.1038/Sj.Gt.3300483 |
0.458 |
|
| 1997 |
Czubayko F, Liaudet-Coopman ED, Aigner A, Tuveson AT, Berchem GJ, Wellstein A. A secreted FGF-binding protein can serve as the angiogenic switch in human cancer. Nature Medicine. 3: 1137-40. PMID 9334727 DOI: 10.1038/Nm1097-1137 |
0.751 |
|
| 1997 |
Rha SY, Noh SH, Kwak HJ, Wellstein A, Kim JH, Roh JK, Min JS, Kim BS, Chung HC. Comparison of biological phenotypes according to midkine expression in gastric cancer cells and their autocrine activities could be modulated by pentosan polysulfate Cancer Letters. 118: 37-46. PMID 9310258 DOI: 10.1016/S0304-3835(97)00215-2 |
0.442 |
|
| 1997 |
Meighan-Mantha RL, Wellstein A, Riegel AT. Differential regulation of extracellular signal-regulated kinase 1 and 2 activity during 12-O-tetradecanoylphorbol 13-acetate-induced differentiation of HL-60 cells Experimental Cell Research. 234: 321-328. PMID 9260900 DOI: 10.1006/Excr.1997.3631 |
0.333 |
|
| 1997 |
Souttou B, Ahmad S, Riegel AT, Wellstein A. Signal transduction pathways involved in the mitogenic activity of pleiotrophin Journal of Biological Chemistry. 272: 19588-19593. PMID 9235965 DOI: 10.1074/Jbc.272.31.19588 |
0.316 |
|
| 1997 |
Kurtz A, Wang HL, Darwiche N, Harris V, Wellstein A. Expression of a binding protein for FGF is associated with epithelial development and skin carcinogenesis Oncogene. 14: 2671-2681. PMID 9178765 DOI: 10.1038/Sj.Onc.1201117 |
0.46 |
|
| 1996 |
Schulte AM, Lai S, Kurtz A, Czubayko F, Riegel AT, Wellstein A. Human trophoblast and choriocarcinoma expression of the growth factor pleiotrophin attributable to germ-line insertion of an endogenous retrovirus Proceedings of the National Academy of Sciences of the United States of America. 93: 14759-14764. PMID 8962128 DOI: 10.1073/Pnas.93.25.14759 |
0.404 |
|
| 1996 |
Czubayko F, Schulte AM, Berchem GJ, Wellstein A. Melanoma angiogenesis and metastasis modulated by ribozyme targeting of the secreted growth factor pleiotrophin Proceedings of the National Academy of Sciences of the United States of America. 93: 14753-14758. PMID 8962127 DOI: 10.1073/Pnas.93.25.14753 |
0.442 |
|
| 1996 |
Liaudet-Coopman EDE, Schulte AM, Cardillo M, Wellstein A. A tetracycline-responsive promoter system reveals the role of a secreted binding protein for FGFs during the early phase of tumor growth Biochemical and Biophysical Research Communications. 229: 930-937. PMID 8954996 DOI: 10.1006/Bbrc.1996.1904 |
0.476 |
|
| 1996 |
Wellstein A, Czubayko F. Inhibition of fibroblast growth factors Breast Cancer Research and Treatment. 38: 109-119. PMID 8825128 DOI: 10.1007/Bf01803789 |
0.397 |
|
| 1996 |
Gottardis MM, Lamph WW, Shalinsky DR, Wellstein A, Heyman RA. The efficacy of 9-cis retinoic acid in experimental models of cancer Breast Cancer Research and Treatment. 38: 85-96. PMID 8825126 DOI: 10.1007/Bf01803787 |
0.347 |
|
| 1996 |
Liaudet-Coopman EDE, Wellstein A. Regulation of gene expression of a binding protein for fibroblast growth factors by retinoic acid Journal of Biological Chemistry. 271: 21303-21308. PMID 8702908 DOI: 10.1074/Jbc.271.35.21303 |
0.396 |
|
| 1995 |
Kurtz A, Schulte AM, Wellstein A. Pleiotrophin and midkine in normal development and tumor biology Critical Reviews in Oncogenesis. 6: 151-177. PMID 8792088 |
0.362 |
|
| 1995 |
Czubayko F, Schulte AM, Missner SC, Hsieh SS, Colley KJ, Wellstein A. Molecular and pharmacologic targeting of angiogenesis factors - the example of pleiotrophin Breast Cancer Research and Treatment. 36: 157-168. PMID 8534864 DOI: 10.1007/Bf00666037 |
0.431 |
|
| 1994 |
Czubayko F, Riegel AT, Wellstein A. Ribozyme-targeting elucidates a direct role of pleiotrophin in tumor growth Journal of Biological Chemistry. 269: 21358-21363. PMID 8063762 |
0.329 |
|
| 1994 |
Tate Riegel A, Wellstein A. The potential role of the heparin-binding growth factor pleiotrophin in breast cancer Breast Cancer Research and Treatment. 31: 309-314. PMID 7533562 DOI: 10.1007/Bf00666163 |
0.45 |
|
| 1994 |
Wellstein A. Growth factor targeted and conventional therapy of breast cancer Breast Cancer Research and Treatment. 31: 141-152. PMID 7533560 DOI: 10.1007/Bf00666148 |
0.438 |
|
| 1994 |
Czubayko F, Smith RV, Chung HC, Wellstein A. Tumor growth and angiogenesis induced by a secreted binding protein for fibroblast growth factors Journal of Biological Chemistry. 269: 28243-28248. PMID 7525570 |
0.412 |
|
| 1993 |
Parker BW, Swain SM, Zugmaier G, Delap RL, Lippman ME, Wellstein A. Detectable inhibition of heparin-binding growth factor activity in sera from patients treated with pentosan polysulfate Journal of the National Cancer Institute. 85: 1068-1073. PMID 7685831 DOI: 10.1093/Jnci/85.13.1068 |
0.372 |
|
| 1993 |
Swain S, Wellstein A, Parker B, Lippman M, Steakley C, DeLap R. Heparin-binding growth factor blockade with pentosan polysulfate Annals of the New York Academy of Sciences. 698: 63-70. PMID 7506507 DOI: 10.1111/J.1749-6632.1993.Tb17191.X |
0.341 |
|
| 1992 |
Wellstein A, Fang W, Khatri A, Lu Y, Swain SS, Dickson RB, Sasse J, Riegel AT, Lippman ME. A heparin-binding growth factor secreted from breast cancer cells homologous to a developmentally regulated cytokine Journal of Biological Chemistry. 267: 2582-2587. PMID 1733956 |
0.339 |
|
| 1992 |
Lai S, Czubayko F, Riegel AT, Wellstein A. Structure of the human heparin-binding growth factor gene pleiotrophin Biochemical and Biophysical Research Communications. 187: 1113-1122. PMID 1530608 DOI: 10.1016/0006-291X(92)91312-E |
0.356 |
|
| 1992 |
Fang W, Hartmann N, Chow DT, Riegel AT, Wellstein A. Pleiotrophin stimulates fibroblasts and endothelial and epithelial cells and is expressed in human cancer Journal of Biological Chemistry. 267: 25889-25897. PMID 1464602 |
0.39 |
|
| 1992 |
Lupu R, Wellstein A, Sheridan J, Ennis BW, Zugmaier G, Katz D, Lippman ME, Dickson RB. Purification and characterization of a novel growth factor from human breast cancer cells Biochemistry. 31: 7330-7340. PMID 1324710 DOI: 10.1021/Bi00147A018 |
0.414 |
|
| 1992 |
Zugmaier G, Lippman ME, Wellstein A. Inhibition by pentosan polysulfate (PPS) of heparin-binding growth factors released from tumor cells and blockage by PPS of tumor growth in animals Journal of the National Cancer Institute. 84: 1716-1724. PMID 1279186 DOI: 10.1093/Jnci/84.22.1716 |
0.454 |
|
| 1991 |
Wellstein A, Zugmaier G, Califano JA, Kern F, Paik S, Lippman ME. Tumor growth dependent on kaposi's sarcoma-derived fibroblast growth factor inhibited by pentosan polysulfate Journal of the National Cancer Institute. 83: 716-720. PMID 1708834 DOI: 10.1093/Jnci/83.10.716 |
0.424 |
|
| 1990 |
Wellstein A, Lupu R, Zugmaier G, Flamm SL, Cheville AL, Delli Bovi P, Basilico C, Lippman ME, Kern FG. Autocrine growth stimulation by secreted Kaposi fibroblast growth factor but not by endogenous basic fibroblast growth factor. Cell Growth & Differentiation : the Molecular Biology Journal of the American Association For Cancer Research. 1: 63-71. PMID 1964794 |
0.333 |
|
| Show low-probability matches. |